Zoetis Inc. $ZTS Position Decreased by Evelyn Partners Investment Management LLP

Evelyn Partners Investment Management LLP decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 11.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 303,314 shares of the company’s stock after selling 37,517 shares during the period. Zoetis makes up 1.1% of Evelyn Partners Investment Management LLP’s portfolio, making the stock its 23rd biggest holding. Evelyn Partners Investment Management LLP’s holdings in Zoetis were worth $38,163,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZTS. Global Wealth Strategies & Associates purchased a new stake in Zoetis during the fourth quarter valued at about $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis during the fourth quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter valued at about $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at about $32,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at about $32,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ZTS shares. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Citigroup reduced their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Zoetis Price Performance

NYSE ZTS opened at $79.51 on Friday. The company has a 50 day simple moving average of $96.94 and a 200-day simple moving average of $114.22. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a market capitalization of $33.33 billion, a price-to-earnings ratio of 13.19, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $167.38.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Insider Activity at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.